Cell therapies for cartilage repair and inflammatory disease, manufactured in-house under EU authorisation.

KELI develops and manufactures cell therapies in Kaunas, Lithuania. Six programmes in cartilage repair, inflammatory disease and fibrosis — one approved, one in a Phase 1b/2 trial.

Cleanroom interior
€3.5M
EU and national grant funding awarded to KELI
Phase 1b/2
CTA submission in progress
1 authorised product
5 in development
2 international patent filings
PCT/EP and USPTO, 2026
2026-527099-98-00
EU clinical trial number

In-house ATMP manufacturing in Kaunas.

KELI GMP cleanroom interior in Kaunas
6
Programmes
Kaunas
Location
Chondrocytes
Platform
Placental MSC
Platform
Grade A–D
Cleanroom

Regulatory expertise in-house.

Two former members of EMA's Committee for Advanced Therapies (CAT) and CHMP lead KELI's regulatory and clinical strategy.

Meet the team

Science and partners.

22 peer-reviewed publications in cartilage repair and MSC research. Two international patent filings.

See the evidence

Clinical partners in Lithuania and letters of intent from cardiac surgery and nephrology centres in Athens, Copenhagen, Essen and Leiden.

See partners

For investors.

KELI is backed by €3.5M in EU and national grants, including a €2.5M EIC Accelerator grant, and is raising a seed round.